Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326603 | 0.99 | CHEK1 (0.36) | CHEK1AURKADAPK3JAK2PRKD3 | |
| Iodide SCHEMBL5323160 | 0.84 | KMT2A (0.38) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL5566386 | 0.84 | KDM4E (0.44) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL5563484 | 0.83 | KMT2A (0.39) | — | |
| SCHEMBL5558771 | 0.78 | ALDH1A1 (0.39) | CHEK1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL4994479 | 0.78 | KMT2A (0.36) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL5570706 | 0.78 | ATP4A (0.40) | — | |
| SCHEMBL5570709 | 0.78 | ATP4A (0.40) | — | |
| SCHEMBL5328510 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 | |
| Bicarbonate SCHEMBL4976269 | 0.77 | KMT2A (0.35) | CYP3A4CYP2D6CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326784-B2 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | ALTANA PHARMA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| WO-2007141253-A1 | PROCESS FOR THE PRODUCTION OF INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC IMIDAZOPYRIDINES | NYCOMED GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | ALTANA PHARMA AG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1697358-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058894-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | CYP1A1, CYP3A4, CYP19A1 | CHEK1 1104/4885AURKA 372/4885DAPK3 2913/4885 |
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | CHEK1 4343/4885AURKA 2569/4885DAPK3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.